EyePoint Pharmaceuticals : EYPT Investor Presentation January 2022

Delivering Innovation to the Eye

Investor Presentation

January 2022

Forward looking statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements

are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of

the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We

cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of

factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

COMPANY OVERVIEW

Pipeline leveraging proven Durasert®

technology *

3 | EYEPOINT PHARMACEUTICALS

Compelling pipeline focused on retinal disease

• EYP-1901- advancing into phase 2 trials for wet AMD, diabetic retinopathy (DR), and retinal vein occlusion (RVO) after positive phase 1 interim results and positive Type C FDA meeting guidance
• Additional molecules and MOAs under evaluation

Durasert® - proven intravitreal (IVT) drug delivery platform

• Sustained local drug delivery
• Constant (zero-order kinetics), stable release of drug in the eye over weeks, months or years
• Safely administered to thousands of patients' eyes across four FDA approved products

Commercial franchises - YUTIQ® and DEXYCU®

• Positioned to break-even in 2022 as stand-alone franchise
• YUTIQ 50 in Phase 3 study supporting an sNDA filing
• DEXYCU sales and marketing now managed by commercial partner ImpriminsRx as we focus on retina

*non-erodible

PLATFORM TECHNOLOGY

DURASERT®

Proven sustained release intravitreal drug delivery

4 | EYEPOINT PHARMACEUTICALS

TECHNOLOGY

DURASERT®

Proven safe, sustained intravitreal delivery

• Delivered by a simple, single in-office intravitreal injection
• Continuous, stable release provides consistent and reliable drug delivery over weeks, months, or years

Approved Products	Development Candidates
▪	YUTIQ® (2018, EyePoint)	▪	EYP-1901
	Posterior Segment Uveitis		▪	Wet AMD
▪	ILUVIEN® (2014, Alimera) - DME
	▪	Diabetic Retinopathy (DR)
▪	RETISERT® (2005, B&L) - Uveitis		▪ Retinal Vein Occlusion (RVO)
▪	VITRASERT® (1996, B&L) - CMV	▪	YUTIQ® 50
	retinitis		▪	Posterior Segment Uveitis

5 | EYEPOINT PHARMACEUTICALS